- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 740573, 8 pages
Prooxidant Mechanisms in Iron Overload Cardiomyopathy
1Department of Medical Research, Tzu Chi General Hospital and Department of Pediatrics, Tzu Chi University, Hualien, Taiwan
2Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
Received 5 June 2013; Accepted 28 October 2013
Academic Editor: Maha Zaki Rizk
Copyright © 2013 Ching-Feng Cheng and Wei-Shiung Lian. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. G. Zurlo, D. P. Stefano, C. Borgna-Pignatti et al., “Survival and causes of death in thalassaemia major,” The Lancet, vol. 2, no. 8653, pp. 27–30, 1989.
- N. F. Olivieri and G. M. Brittenham, “Iron-chelating therapy and the treatment of thalassemia,” Blood, vol. 89, no. 3, pp. 739–761, 1997.
- E. D. Thomas, C. D. Buckner, and J. E. Sanders, “Marrow transplantation for thalassaemia,” The Lancet, vol. 2, no. 8292, pp. 227–229, 1982.
- I. Roberts, “Current status of allogeneic transplantation for haemoglobinopathies,” British Journal of Haematology, vol. 98, no. 1, pp. 1–7, 1997.
- “Third internationalsymposium on BMT in thalassemia,” Bone Marrow Transplant, vol. 19, supplement 2, pp. 1–206, 1997.
- C. Giardini, M. Galimberti, G. Lucarelli et al., “Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassaemia,” British Journal of Haematology, vol. 89, no. 4, pp. 868–873, 1995.
- P. Liu and N. Olivieri, “Iron overload cardiomyopathies: new insights into an old disease,” Cardiovascular Drugs and Therapy, vol. 8, no. 1, pp. 101–110, 1994.
- M. A. Aldouri, B. Wonke, A. V. Hoffbrand et al., “High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation,” Acta Haematologica, vol. 84, no. 3, pp. 113–117, 1990.
- J. W. Hou, M. H. Wu, K. H. Lin, and H.-C. Lue, “Prognostic significance of left ventricular diastolic indexes in β- thalassemia major,” Archives of Pediatrics and Adolescent Medicine, vol. 148, no. 8, pp. 862–866, 1994.
- M. A. Engle, M. Erlandson, and C. H. Smith, “Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis,” Circulation, vol. 30, pp. 698–705, 1964.
- W. J. Bartfay, F. Dawood, W. H. Wen et al., “Cardiac function and cytotoxic aldehyde production in a murine model of chronic iron-overload,” Cardiovascular Research, vol. 43, no. 4, pp. 892–900, 1999.
- J. C. Wood, “Cardiac iron across different transfusion-dependent diseases,” Blood Reviews, vol. 22, supplement 2, pp. S14–S21, 2008.
- J. B. Porter, “Concepts and goals in the management of transfusional iron overload,” American Journal of Hematology, vol. 82, no. 12, pp. 1136–1139, 2007.
- G. Y. Oudit, M. G. Trivieri, N. Khaper, P. P. Liu, and P. H. Backx, “Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy,” Journal of Molecular Medicine, vol. 84, no. 5, pp. 349–364, 2006.
- C. Hershko, G. Link, and I. Cabantchik, “Pathophysiology of iron overload,” Annals of the New York Academy of Sciences, vol. 850, pp. 191–201, 1998.
- E. W. Randell, J. G. Parkes, N. F. Olivieri, and D. M. Templeton, “Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron,” Journal of Biological Chemistry, vol. 269, no. 23, pp. 16046–16053, 1994.
- R. G. Tsushima, A. D. Wickenden, R. A. Bouchard, G. Y. Oudit, P. P. Liu, and P. H. Backx, “Modulation of iron uptake in heart by L-type Ca2+ channel modifiers: possible implications in iron overload,” Circulation Research, vol. 84, no. 11, pp. 1302–1309, 1999.
- G. Y. Oudit, H. Sun, M. G. Trivieri et al., “L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy,” Nature Medicine, vol. 9, no. 9, pp. 1187–1194, 2003.
- D. T. Kremastinos, D. P. Tsiapras, G. A. Tsetsos, E. I. Rentoukas, H. P. Vretou, and P. K. Toutouzas, “Left ventricular diastolic Doppler characteristics in β-thalassemia major,” Circulation, vol. 88, no. 3, pp. 1127–1135, 1993.
- N. F. Olivieri, G. M. Brittenham, D. Matsui et al., “Iron-chelation therapy with oral deferipronein patients with thalassemia major,” New England Journal Medicine, vol. 332, no. 14, pp. 918–922, 1995.
- S. Crowe and W. J. Bartfay, “Amlodipine decreases iron uptake and oxygen free radical production in the heart of chronically iron overloaded mice,” Biological Research for Nursing, vol. 3, no. 4, pp. 189–197, 2002.
- S. Kumfu, S. Chattipakorn, K. Chinda, S. Fucharoen, and N. Chattipakorn, “T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice,” European Journal of Haematology, vol. 88, no. 6, pp. 535–548, 2012.
- S. Kumfu, S. Chattipakorn, S. Fucharoen, and N. Chattipakorn, “Ferric iron uptake into cardiomyocytes of β-thalassemic mice is not through calcium channels,” Drug and Chemical Toxicology, vol. 36, no. 3, pp. 329–334, 2013.
- A. O. Jorgensen, A. C.-Y. Shen, W. Arnold, P. S. McPherson, and K. P. Campbell, “The Ca2+-release channel/ryanodine receptor is localized in junctional and corbular sarcoplasmic reticulum in cardiac muscle,” Journal of Cell Biology, vol. 120, no. 4, pp. 969–980, 1993.
- E. Kim, S. N. Giri, and I. N. Pessah, “Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum,” Toxicology and Applied Pharmacology, vol. 130, no. 1, pp. 57–66, 1995.
- R. A. Rose, M. Sellan, J. A. Simpson et al., “Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation,” Circulation, vol. 4, no. 5, pp. 733–742, 2011.
- G. J. Quinlan, T. W. Evans, and J. M. C. Gutteridge, “Iron and the redox status of the lungs,” Free Radical Biology and Medicine, vol. 33, no. 10, pp. 1306–1313, 2002.
- X. Gao, J. L. Campian, M. Qian, X. Sun, and J. W. Eaton, “Mitochondrial DNA damage in iron overload,” Journal of Biological Chemistry, vol. 284, no. 8, pp. 4767–4775, 2009.
- X. Gao, M. Qian, J. L. Campian et al., “Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload,” Free Radical Biology and Medicine, vol. 49, no. 3, pp. 401–407, 2010.
- J. H. Jackson, I. U. Schraufstatter, P. A. Hyslop et al., “Role of oxidants in DNA damage. Hydroxyl radical mediates the synergistic DNA damaging effects of asbestos and cigarette smoke,” Journal of Clinical Investigation, vol. 80, no. 4, pp. 1090–1095, 1987.
- I. Schraufstatter, P. A. Hyslop, J. H. Jackson, and C. G. Cochrane, “Oxidant-induced DNA damage of target cells,” Journal of Clinical Investigation, vol. 82, no. 3, pp. 1040–1050, 1988.
- H. U. Enright, W. J. Miller, and R. P. Hebbel, “Nucleosomal histone protein protects DNA from iron-mediated damage,” Nucleic Acids Research, vol. 20, no. 13, pp. 3341–3346, 1992.
- H. Enright, K. A. Nath, R. P. Hebbel, and S. L. Schrier, “Internucleosomal cleavage of DNA is insufficient evidence to conclude that cell death is apoptotic,” Blood, vol. 83, no. 7, pp. 2005–2007, 1994.
- F. M. Yakes and B. Van Houten, “Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 2, pp. 514–519, 1997.
- J. J. Salazar and B. Van Houten, “Preferential mitochondrial DNA injury caused by glucose oxidase as a steady generator of hydrogen peroxide in human fibroblasts,” Mutation Research, vol. 385, no. 2, pp. 139–149, 1997.
- M. Shvartsman, R. Kikkeri, A. Shanzer, and Z. I. Cabantchik, “Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications,” American Journal of Physiology, vol. 293, no. 4, pp. C1383–C1394, 2007.
- M. Shvartsman, E. Fibach, and Z. I. Cabantchik, “Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence,” Biochemical Journal, vol. 429, no. 1, pp. 185–193, 2010.
- R. Bolli, B. S. Patel, W.-X. Zhu et al., “The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction,” American Journal of Physiology, vol. 253, no. 6, pp. H1372–H1380, 1987.
- A. M. M. van der Kraaij, H. G. van Eijk, and J. F. Koster, “Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3,” Circulation, vol. 80, no. 1, pp. 158–164, 1989.
- W. S. Lian, H. Lin, W. T. K. Cheng, T. Kikuchi, and C. F. Cheng, “Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy,” Journal of Biomedical Science, vol. 18, p. 26, 2011.
- M. Harada, Y. Qin, H. Takano et al., “G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes,” Nature Medicine, vol. 11, no. 3, pp. 305–311, 2005.
- S. Minatoguchi, G. Takemura, X. Chen et al., “Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment,” Circulation, vol. 109, no. 21, pp. 2572–2580, 2004.
- M. Ohtsuka, H. Takano, Y. Zou et al., “Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization,” The FASEB Journal, vol. 18, no. 7, pp. 851–853, 2004.
- E. Deindl, M. Zaruba, S. Brunner et al., “G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis,” The FASEB Journal, vol. 20, no. 7, pp. 956–958, 2006.
- L. Li, G. Takemura, Y. Li et al., “Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy,” Laboratory Investigation, vol. 87, no. 5, pp. 440–455, 2007.
- S. M. Day, D. Duquaine, L. V. Mundada et al., “Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis,” Circulation, vol. 107, no. 20, pp. 2601–2606, 2003.
- Z. Cheng, L. Ou, Y. Liu et al., “Granulocyte colony-stimulating factor exacerbates cardiac fibrosis after myocardial infarction in a rat model of permanent occlusion,” Cardiovascular Research, vol. 80, no. 3, pp. 425–434, 2008.
- Z. Cheng, X. Liu, L. Ou et al., “Mobilization of mesenchymal stem cells by granulocyte colony-stimulating factor in rats with acute myocardial infarction,” Cardiovascular Drugs and Therapy, vol. 22, no. 5, pp. 363–371, 2008.
- E. Stoyanova, G. Cloutier, H. Felfly, W. Lemsaddek, N. Ah-Son, and M. Trudel, “Evidence for a novel mechanism independent of myocardial iron in beta-thalassemia cardiac pathogenesis,” PloS ONE, vol. 7, Article ID e52128, 2012.
- L. C. Skow, B. A. Burkhart, and F. M. Johnson, “A mouse model for β-thalassemia,” Cell, vol. 34, no. 3, pp. 1043–1052, 1983.
- E. Stoyanova, M. Trudel, H. Felfly, D. Garcia, and G. Cloutier, “Characterization of circulatory disorders in β-thalassemic mice by noninvasive ultrasound biomicroscopy,” Physiological Genomics, vol. 29, no. 1, pp. 84–90, 2007.
- R. Mattera, G. P. Stone, N. Bahhur, and Y. A. Kuryshev, “Increased release of arachidonic acid and eicosanoids in iron-overloaded cardiomyocytes,” Circulation, vol. 103, no. 19, pp. 2395–2401, 2001.
- G. Johnson III, L. E. Furlan, N. Aoki, and A. M. Lefer, “Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats,” Circulation Research, vol. 66, no. 5, pp. 1362–1370, 1990.
- H. Lin, H. F. Li, W. S. Lian et al., “Thromboxan A2 mediates iron-overload cardiomyopathy in mice through calcinurin-NFAT signaling pathway,” Circulation Journal, vol. 77, no. 10, pp. 2586–2595, 2013.
- T. Cyrus, T. Ding, and D. Praticò, “Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition,” Atherosclerosis, vol. 208, no. 2, pp. 376–381, 2010.
- N. G. Forouhi, A. H. Harding, M. Allison et al., “Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study,” Diabetologia, vol. 50, no. 5, pp. 949–956, 2007.
- O. A. Mojiminiyi, R. Marouf, and N. A. Abdella, “Body iron stores in relation to the metabolic syndrome, glycemic control and complications in female patients with type 2 diabetes,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 8, pp. 559–566, 2008.
- B. J. Ku, S. Y. Kim, T. Y. Lee, and K. S. Park, “Serum ferritin is inversely correlated with serum adiponectin level: population-based cross-sectional study,” Disease Markers, vol. 27, no. 6, pp. 303–310, 2009.
- J. S. Gabrielsen, Y. Gao, J. A. Simcox et al., “Adipocyte iron regulates adiponectin and insulin sensitivity,” The Journal of Clinical Investigation, vol. 122, no. 10, pp. 3529–3540, 2012.
- E. Kahn, M. Baarine, S. Pelloux et al., “Iron nanoparticles increase 7-ketocholesterol-induced cell death, inflammation, and oxidation on murine cardiac HL1-NB cells,” International Journal of Nanomedicine, vol. 5, no. 1, pp. 185–195, 2010.
- H. Lin, W. S. Lian, H. H. Chen, P. F. Lai, and C. F. Cheng, “Adiponectin ameliorates iron-overload cardiomyopathy through the PPARα-PGC-1-dependent signaling pathway,” Molecular Pharmacology, vol. 84, no. 2, pp. 275–285, 2013.
- J. Davignon, “Beneficial cardiovascular pleiotropic effects of statins,” Circulation, vol. 109, no. 23, pp. III39–III43, 2004.
- J. K. Liao and U. Laufs, “Pleiotropic effects of statins,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 89–118, 2005.
- U. Grandel, L. Fink, A. Blum et al., “Endotoxin-induced myocardial tumor necrosis factor-α synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production,” Circulation, vol. 102, no. 22, pp. 2758–2764, 2000.
- H. Katagiri, Y. Ito, S. Ito et al., “TNF-α induces thromboxane receptor signaling-dependent microcirculatory dysfunction in mouse liver,” Shock, vol. 30, no. 4, pp. 463–467, 2008.